Recursion in the News: Latest Press Coverage

These articles are written and published by sources outside Recursion. Recursion is not responsible for and has no control over the subject matter, content, graphics or privacy policies and practices of the linked websites, nor the platforms on which they are published.

Recursion in the News: Latest Press Coverage

Chris Gibson Discusses Combination Deal with Exscientia on Bloomberg: The Close

Trans-Atlantic Triumph: AI Drug Pioneers Recursion, Exscientia Combine

Recursion Advances AI-Based C. Diff Candidate to Phase II

Recursion’s Fast-Track Road to Therapeutics Using AI-Based Maps of Biology

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

Creating an AI-first drug discovery engine

AI's Drug Revolution, Part 2: New Uses for Old Drugs

InnovationRx: Recursion’s CEO talks clinical trial data for AI-designed drug

Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

After a tough year, Exscientia folds into Recursion to create an AI superpower

AI drug developers Recursion, Exscientia to merge

Recursion to Acquire Exscientia, Combining AI Drug Pioneers

Recursion to buy AI rival Exscientia

Recursion CEO Chris Gibson on Accelerating the Biopharmaceutical Industry With AI

Artificial Intelligence Reveals Protein-DNA Interactions

Investors want proof AI will aid drug discovery. Evidence may come in the second half

Recursion CEO Chris Gibson talks integrating AI into drug development process

Recursion Completes Supercomputer for AI Drug Discovery

Chutes & Ladders—Recursion makes big executive splash, nabs J&J's chief data science officer

The Intersection Of Tech and Biotech with Chris Gibson

Recursion partners with NVIDIA to unveil Phenom-Beta, democratizing access to its $1 Billion phenomics investment

Recursion Announces New Generative AI Platform To Speed Up Drug Discovery

Recursion Wants to 4X Its Supercomputing Power for AI With the Help of Nvidia. Here's Why It Matters.

Recursion Pharma Sharpens Oncology Focus with Potential $1.5B Bayer Collaboration

Recursion Pharmaceuticals has a prescription for high drug costs: AI and 25 petabytes of data

Recursion Screens Protein-Small Molecule Interactions at Vast Scale

‘We look like what the future of all biopharma companies will look like’, says Recursion CEO Gibson

Trillion-dollar partner: Recursion raises $50M from Nvidia, stock skyrockets

Nvidia deepens bets on AI in drug discovery with Recursion investment

Recursion CEO Chris Gibson: There’s real opportunity to leverage A.I. to speed up drug development

Recursion acquires two AI-based drug discovery companies in $87.5M deal

A technique called Cell Painting could speed drug discovery

The 10 most innovative biotech companies of 2023

The 8 leading biotechs using AI to upend how drugs are discovered

The CEO of a $1.6 billion biotech says his bet on AI is paying off with faster, cheaper research that could reshape the industry

How Recursion Hopes to Harness the Big Picture View to Understand Biology’s Landscape

AI use in repurposing drugs for Covid-19

Recursion Pharmaceuticals Puts Strength on Full Display

The Netflix of Digital Biology? Recursion Is Reimagining Drug Discovery

Recursion: Policies and Practices that Attract, Retain, and Advance Women

Companies are gaining an edge during The Great Resignation by doing more to help parents through the ‘chaos years’

Chris Gibson on Industrializing Drug Discovery

Harnessing the Power of AI

Roche Signs Machine-Learning Neuroscience Deal With Recursion

Recursion Pharmaceuticals Raises $239 Million and Partners with Bayer for AI Drug Discovery

Decoding biology to radically improve lives.

Get In Touch

Policies

Connect